Na Mee 2022, Shenzhen JYMed Technology Co., Ltd. (nke a na-akpọ JYMed peptide) nyefere ngwa maka ndebanye aha API semaglutide na US Food and Drug Administration (FDA) (nọmba ndebanye aha DMF: 036009), Ọ gafere. nyochaa iguzosi ike n'ezi ihe, na ọnọdụ dị ugbu a bụ "A". JYMed peptide aghọwo otu n'ime ndị mbụ na-emepụta semaglutide API na China gafere nyocha US FDA.

Na Febụwarị 16, 2023, webụsaịtị gọọmentị nke Center Evaluation Center nke State Drug Administration kwupụtara na semaglutide API [nọmba ndebanye aha: Y20230000037] debara aha ma kwupụta ya site na Hubei JXBio Co., Ltd., onye enyemaka nke JYMed peptide. nabatara. JYMed peptide abụrụla otu n'ime ndị na-emepụta ọgwụ akụrụngwa mbụ nke anabatara ngwa ahịa maka ngwaahịa a na China.

Banyere semaglutide
Semaglutide bụ onye na-anabata GLP-1 nke Novo Nordisk (Novo Nordisk) mepụtara. Ọgwụ ahụ nwere ike ịbawanye metabolism nke glucose site na ịkpali mkpụrụ ndụ beta pancreatic iji wepụta insulin, ma gbochie secretion nke glucagon site na mkpụrụ ndụ α pancreatic iji belata ibu ọnụ na shuga ọbara mgbe nri gasịrị. Na mgbakwunye, ọ na-ebelata oriri oriri site n'ibelata agụụ na ibelata mgbari afọ na afọ, nke na-emecha na-ebelata abụba anụ ahụ ma na-enye aka n'ibelata ibu.
1. Ozi isi
Site n'echiche nhazi, ma e jiri ya tụnyere liraglutide, nnukwu mgbanwe nke semaglutide bụ na agbakwunyere AEEA abụọ n'akụkụ akụkụ nke lysine, na octadecanedioic acid dochie palmitic acid. Aib nọchiri Alanine, nke gbatịpụrụ ọkara ndụ nke semaglutide nke ukwuu.

Ihe onyonyo nke semaglutide

2. Ngosipụta
1) Semaglutide nwere ike belata ihe ize ndụ nke ihe omume obi na ndị ọrịa nwere T2D.
2) Semaglutide na-ebelata shuga ọbara site n'ịkwalite insulin secretion na ibelata glucagon secretion. Mgbe shuga dị n'ọbara dị elu, a na-akpali mmepụta insulin ma na-egbochi secretion glucagon.
3) Novo Nordisk PIONEER nnwale ụlọ ọgwụ gosiri na nchịkwa ọnụ nke semaglutide 1mg, 0.5mg nwere mmetụta hypoglycemic dị mma na oke ibu karịa Trulicity (dulaglutide) 1.5mg, 0.75mg.
3) Oral semaglutide bụ kaadị opi nke Novo Nordisk. Nlekọta ọnụ otu ugboro n'ụbọchị nwere ike iwepụ nsogbu ahụ na mmekpa ahụ nke mmụọ nke ịgba ọgwụ na-akpata, yana ọ ka mma karịa liraglutide (ịgba ọgwụ mgbochi otu ugboro n'izu). Mmetụta hypoglycemic na mbelata ibu nke ọgwụ ndị bụ isi dị ka, empagliflozin (SGLT-2) na sitagliptin (DPP-4) na-adọrọ mmasị ndị ọrịa na ndị dọkịta. E jiri ya tụnyere usoro ịgba ọgwụ, usoro ọnụ ga-eme ka ịdị mma nke ngwa ọgwụ semaglutide dịkwuo mma.

3. Nchịkọta
Ọ bụ kpọmkwem n'ihi arụmọrụ ya dị mma na hypoglycemic, mbelata ibu, nchekwa na uru obi na semaglutide abụrụla ihe ngosi “kpakpando ọhụrụ” nwere nnukwu atụmanya ahịa.